Explore a groundbreaking webinar on CD3ζ as a novel integration site for reprogramming immune cells with Chimeric Antigen Receptors, presented by Dr. Dimitrios L. Wagner, head of Research and Development Unit at Berlin Center for Advanced Therapies. Delve into the exciting therapeutic potential of CAR-reprogrammed immune cells for oncology, autoimmune diseases, transplant medicine, and infections. Examine the challenges of current CAR-T therapies, including CAR-signaling regulation and limited accessibility due to expensive personalized manufacturing. Gain insights into innovative approaches to overcome these limitations and advance the field of immunotherapy. Earn PACE credits by watching the webinar and following the provided instructions. Connect with Labroots on various social media platforms for more scientific content and updates.
CD3ζ as a Novel Integration Site for Reprogramming Immune Cells with Chimeric Antigen Receptors
Overview
Syllabus
CD3ζ as a novel integration site for reprogramming immune cells with Chimeric Antigen Receptors
Taught by
Labroots
Related Courses
-
Engineering Enhanced Chimeric Antigen Receptor T-Cell Therapy
-
Selective Depletion of CD45RA Expressing Cells to Enrich Antigen-Specific T-Cells for Immunotherapy
-
Next Generation Genetic Discovery Systems in Human Immune Cells
-
Identification of Tumor-Reactive T Cell Receptors Through Functional Single Cell Interaction Analysis for Personalized T Cell Therapy
-
Monitoring of Circulating CAR T Cells
-
Optimizing CAR Structures to Enhance Efficacy in Solid Tumors - Moving from Linear to Lateral Architectures
